Sensibilización a bisfenol A y bisfenol F en trabajadores expuestos a resinas epoxi / No disponible

Las aplicaciones de las diferentes resinas epoxi basadas en bisfenol A y F son extensas. Las resinas epoxi basadas en bisfenol F son más nuevas y resistentes que las de bisfenol A, y ambas son causa conocida de dermatitis de contacto alérgica. Se estudian 39 casos de sensibilización a resinas epoxi en los últimos 5 años. Los resultados obtenidos son: prevalencia de sensibilización a resinas epoxi entre los pacientes estudiados del 2%, 27 varones y 8 mujeres, con una edad media de 42.77, un período de medio sensibilización de 23,8 meses. La sensibilización a bisfenol F desde que se incluye para las pruebas del parche en la batería de resinas epoxi es del 100% para los casos sensibilizados a la resina. La localización mayoritaria se dio en las manos, con una relevancia actual del 84%. Se recomendó un cambio de puesto en el trabajo al 46% de estos pacientes. El aumento de la sensibilización encontrada a bisfenol F puede explicarse por una sensibilización concomitante con bisfenol A, una declaración incorrecta de la composición de la resina o una reactividad cruzada de ambos

The applications of epoxy resins based on bisphenol A and F are extensive. Epoxy resins based on bisphenol F are new and more resistant than epoxy resins based on bisphenol A. Both of them cause allergic contact dermatitis. In the last 5 years, we have studied 39 cases of sensitization to epoxy resin. The results of our study were these: the global prevalence of epoxy resin sensitization was 2%, 27 men and 8 women. The mean age was 42.77 years and the sensitization period was 23.8 months. The most frequent localization of the lesions were hands (84% of the patients). Since bisphenol F was included in epoxy resin battery for patch testing, a 100% of positives responses in patients sensitized to epoxy resin have been found. Sensitization to epoxy resins was a cause of change in workplace in 46% of cases in our series. There has been an increase in sensitization of bisphenol F that could be explained by a concomitant sensitization with bisphenol A, cross-reactivity between bisphenol A and F or because an incorrect chemical compound information of the resin

Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates.

Hermansky-Pudlak syndrome is a rare autosomal recessive disorder characterized by the absence of platelet dense bodies in association with albinism. We present the use of recombinant activated factor VII (rFVIIa) in a patient with Hermansky-Pudlak syndrome who underwent total thyroidectomy because of a large richly vascularized nodule (10 cm) compressing the trachea. The patient had a prolonged bleeding time (> 20 min) that remained unchanged after platelet transfusions. However, after infusion of platelets plus rFVIIa, it diminished to 5 min. The platelet aggregation response to adenosine diphosphate and collagen was diminished. Since an early age, the patient had repeated nose bleeding and an episode of melena requiring several tampons, cauterization and transfusions of packed red cells. In this case, we used rFVIIa in bolus for 1 day (four doses of 120 microg/kg every 2 h and six doses of 100 microg/kg every 3 h) and transfusion of platelet concentrates beginning just prior to surgery. No evidence of local bleeding complication could be detected during the entire post-operative period. The hemoglobin level remained normal and no transfusions of packed red cells were necessary. No adverse events occurred.